

Patient card

Erivedge may harm the fetus or cause its death.

Female patients who can become pregnant must:

- Always use 2 types of the recommended contraceptives throughout the course of the treatment and during the 24 months after the last dose is taken. (Please consult the Erivedge Contraception Plan brochure for additional information).
- Perform a pregnancy test once a month in order to monitor for pregnancy.

Male patients must:

- Use a condom (which contains spermicide, if possible) at all times during sexual intercourse with a woman throughout the course of the treatment and during the 2 months after the last dose is taken.
- Do not donate sperm during the course of the treatment or during the two months after the last dose is taken.

You must immediately consult your doctor if your menstrual period or your sexual partner's menstrual period is delayed; or if there is a suspicion of pregnancy or a pregnancy.

- Female patients - Consult your doctor if you suspect you might be pregnant during the course of the treatment or during the 24 months after the last dose was taken.
- Male patients- Consult your doctor if your partner suspects that she is pregnant during the course of the treatment with Erivedge or during the 2 months after the last dose was taken.

All patients:

- Do not donate blood during the course of the treatment or within 24 months of taking the last dose.
- Do not give this medication to any other person.

Side effects may be reported to the Ministry of Health using the online form for the reporting of adverse events on the homepage of the Ministry of Health at www.health.gov.il, or by clicking on the link <https://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il>

or to Roche company at the following email address Israel.DrugSafety@roche.com

Emergency phone numbers:

--